# A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

> **NCT07485920** · PHASE4 · NOT_YET_RECRUITING · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 20 (estimated)

## Conditions studied

- Limited-stage Small Cell Lung Cancer (LS-SCLC)

## Interventions

- **DRUG:** Tislelizumab and nintedanib

## Key facts

- **NCT ID:** NCT07485920
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-12-10
- **Final completion:** 2030-01-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07485920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07485920, "A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07485920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*